Efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/  refractory multiple myeloma: a real-life experience

Nur SOYER; Püsem PATIR; Ayşe UYSAL; Mustafa DURAN; Hatice Demet Kiper ÜNAL; İsabel Raika Durusoy ONMUŞ; Murat TOMBULOĞLU; Fahri ŞAHİN; Mahmut TÖBÜ; Filiz VURAL; Güray SAYDAM

Makale detayları

Efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/ refractory multiple myeloma: a real-life experience

Yazarlar:

Nur SOYER | Püsem PATIR | Ayşe UYSAL | Mustafa DURAN | Hatice Demet Kiper ÜNAL | İsabel Raika Durusoy ONMUŞ | Murat TOMBULOĞLU | Fahri ŞAHİN | Mahmut TÖBÜ | Filiz VURAL | Güray SAYDAM

Yayıncı:

TUBITAK

Dergi:

Turkish Journal of Medical Sciences 2018 Vol.48 Issue 4, pp.777-785

Belge Tipi:

Makale

Yayın Tarihi:

7/2018

Belge Dili:

Türkçe

Document ID (Org No.):

2000750635

Sıklık:

İki Aylık

eISSN:

1303-6165

pISSN:

1300-0144

Özet:

 

Background/aim: In Turkey, lenalidomide plus dexamethasone (RD) has been used to treat relapsed/refractory multiple myeloma  (RRMM) since 2010. This retrospective, single-center study evaluated the efficacy and tolerability of RD in patients with RRMM  between October 2010 and June 2016.  Materials and methods: Patients' records were reviewed, and overall (OS) and progression-free survival (PFS) were assessed.  Results: One hundred and twenty patients (71 males; 59.2%) were included in the study. The median number of prior lines of treatment  was one (1-4); 72 patients (60.0%) received RD as second-line therapy and 51 patients (42.5%) had previously undergone autologous  stem cell transplantation (ASCT). The overall response rate was 72.5%, with 19% of these patients achieving a complete response. The  median length of follow-up and duration of response to RD was 14 months and 19 months, respectively. Median OS and PFS were 32  and 21 months, respectively. Prior ASCT, an overall response, and treatment with RD for >12 cycles were identified as independent  prognostic factors for OS and PFS. Adverse events (AEs) occurred in 69 (57.5%) and 14 patients (11.7%) discontinued treatment due  to AEs.  Conclusions: We found RD to be safe, well tolerated, and effective in RRMM in everyday clinical practice in Turkey.

Makale detayları

Efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/ refractory multiple myeloma: a real-life experience

Yazarlar: Nur SOYER | Püsem PATIR | Ayşe UYSAL | Mustafa DURAN | Hatice Demet Kiper ÜNAL | İsabel Raika Durusoy ONMUŞ | Murat TOMBULOĞLU | Fahri ŞAHİN | Mahmut TÖBÜ | Filiz VURAL | Güray SAYDAM

Yayıncı: TUBITAK

Dergi: Turkish Journal of Medical Sciences 2018 Vol.48 Issue 4, pp.777-785

Belge Tipi: Makale

Yayın Tarihi: 7/2018

Belge Dili: Türkçe

Document ID (Org No.): 2000750635

Sıklık: İki Aylık

eISSN: 1303-6165

pISSN: 1300-0144

Sayı

Yazarlar:

Nur SOYER | Püsem PATIR | Ayşe UYSAL | Mustafa DURAN | Hatice Demet Kiper ÜNAL | İsabel Raika Durusoy ONMUŞ | Murat TOMBULOĞLU | Fahri ŞAHİN | Mahmut TÖBÜ | Filiz VURAL | Güray SAYDAM

Yayıncı:

TUBITAK

Dergi:

Turkish Journal of Medical Sciences 2018 Vol.48 Issue 4, pp.777-785

Belge Tipi:

Makale

Yayın Tarihi:

7/2018

Belge Dili:

Türkçe

Document ID (Org No.):

2000750635

Sıklık:

İki Aylık

eISSN:

1303-6165

pISSN:

1300-0144